Document is current

Any future updates will be listed below

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

Crossref DOI link: https://doi.org/10.1007/s12325-021-01656-3

Published Online: 2021-04-15

Published Print: 2021-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark